PCOS Renamed to PMOS: What the New Name Means for Your Fertility
Quick Answer
In May 2026, PolyCystic Ovary Syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a 14-year global review led by the Endocrine Society and more than 50 patient and professional organizations.
The new name reflects what research has confirmed: this is a hormonal and metabolic condition, not a disease of ovarian cysts. A three-year transition period began in 2026, with full implementation expected in the 2028 International Guideline update.
PCOS is Now PMOS: What Just Happened
On May 12, 2026, the Endocrine Society and a global coalition of 56 patient and professional organizations announced that PCOS would be renamed polyendocrine metabolic ovarian syndrome (PMOS).
The change was led by Professor Helena Teede of Monash University, alongside the International Androgen Excess and PCOS Society and patient advocacy group Verity (PCOS UK), and was published in The Lancet.
The decision followed a 14-year process involving more than 22,000 survey responses from patients and healthcare professionals across all major world regions.
According to the Endocrine Society, it is the largest initiative ever undertaken to change the name of a medical condition.
Why PCOS Was Renamed to PMOS
The name “polycystic ovary syndrome” suggested that the defining feature of the condition was the presence of abnormal cysts on the ovaries. Research now confirms this is inaccurate.
What appears on ultrasound as cysts are actually arrested follicles, partly developed eggs that have stopped maturing. They are not true cysts, and they do not occur in greater numbers than in women without the condition.
PCOS also narrowed clinical focus to a single organ. In practice, the condition affects multiple systems:
- Hormonal: elevated androgens, disrupted ovulation
- Metabolic: insulin resistance, weight changes
- Reproductive: irregular cycles, anovulation, infertility
- Dermatological: acne, excess hair growth, hair loss
- Mental health: increased rates of anxiety and depression
Because the name PCOS focused only on the ovary, many women with hormonal and metabolic symptoms were misdiagnosed, dismissed, or experienced significant delays in diagnosis.
The average wait between symptom onset and diagnosis has historically been several years, and many women have only received a diagnosis when seeking help for infertility.
What PMOS Stands For
Each word in the new name was chosen to reflect a specific aspect of the condition.
| Term | What it means |
| Polyendocrine | Multiple hormonal systems are involved, not only the ovaries |
| Metabolic | The condition affects how the body processes insulin, glucose, and fat |
| Ovarian | The ovaries remain a central site of dysfunction, particularly in egg development and ovulation |
| Syndrome | A collection of symptoms that occur together, varying between patients |
The word “reproductive” was deliberately avoided. In some cultural contexts, tying a condition explicitly to reproduction can create stigma or harm for women in regions where fertility is closely linked to social value.
The new name remains scientifically accurate without amplifying that risk.
What Changes and What Stays the Same
For women currently diagnosed with PCOS, the rename to PMOS does not require any immediate action.
| What changes | What stays the same |
| The clinical name used in new diagnoses, guidelines, and research | Your existing diagnosis remains valid |
| Educational materials and patient resources will be updated globally | Symptoms and diagnostic criteria do not change |
| Health professional training will reflect the broader systemic understanding | Treatment options remain the same |
| Insurance coding and medical records will transition over three years | Existing medications, monitoring, and follow-up plans continue |
A three-year transition period runs from 2026 to 2028. During that time, both names will appear in clinical documentation, research, and patient resources.
Full integration into the International Evidence-Based Guideline is scheduled for the 2028 update.
Why This Matters for Your Fertility
PMOS is one of the most common causes of female infertility. Studies estimate that 70 to 80% of women with the condition experience infertility, and it accounts for a significant share of ovulatory dysfunction in women seeking fertility care.
The new name aligns clinical understanding with what fertility specialists have observed for years: managing the condition for fertility outcomes requires treating it as a hormonal and metabolic disorder, not only an ovarian one.
Three things change for you under the new framework:
- Your diagnosis may be more thorough: Under the PMOS framework, fertility assessments more consistently evaluate hormonal, metabolic, and reproductive markers together. If you have been diagnosed based mainly on ovarian findings in the past, expect a broader workup if you start fertility care now.
- Your treatment plan is more likely to address the right driver: PMOS affects each patient differently. Some women have predominantly metabolic features, others predominantly reproductive ones. The new framework supports treatment plans that target the specific factors affecting your fertility, rather than applying a generic protocol.
- Your long-term health gets more attention from the start: Women with PMOS face elevated long-term risks for type 2 diabetes, cardiovascular disease, and endometrial issues. A fertility consultation is now a natural moment to flag and start managing these risks early, not only to address pregnancy goals.
Fertility Treatment for Women With PMOS
Treatment depends on the specific features of the condition and the patient’s age, ovarian reserve, and overall health. Standard approaches include:
- Lifestyle and metabolic management as a first-line intervention, particularly for patients with insulin resistance or weight-related contributions to anovulation
- Ovulation induction with oral medications such as letrozole or clomiphene citrate
- Metformin in select cases to support insulin sensitivity and ovulation
- IUI when ovulation can be induced but pregnancy has not occurred after a defined trial period
- IVF when first-line treatments have not been successful, or when other fertility factors are present
PMOS patients often respond well to ovulation induction. However, they also require careful monitoring during fertility treatment because the condition increases the risk of ovarian hyperstimulation syndrome (OHSS) when injectable hormones are used.
Treatment protocols are adjusted accordingly.
How Markham Fertility Centre Approaches PMOS
- PMOS assessment is integrated into the initial fertility evaluation, including hormonal, metabolic, and ovarian reserve testing
- Personalized stimulation protocols for patients with PMOS, including modified natural cycle and antagonist protocols to reduce OHSS risk
- Coordination with broader specialist care when metabolic or endocrine management is needed alongside fertility treatment
- Monitoring of long-term cardiometabolic risks, including insulin resistance and elevated diabetes risk, that often accompany PMOS
- Five locations across Markham, Barrie-Innisfil, Oshawa, Orillia, and Sudbury
- Ontario Fertility Program participant for funded IVF cycles
Book a fertility assessment at Markham Fertility Centre →
FAQ
Is PMOS a different condition from PCOS?
No. PMOS and PCOS describe exactly the same condition. The name change reflects updated scientific understanding, not a new disease. A past PCOS diagnosis carries forward as PMOS with no clinical differences.
Do I need a new diagnosis if I already have PCOS?
No. Your existing diagnosis remains valid. Symptoms, diagnostic criteria, and treatment options are unchanged. Medical records will transition to PMOS over the three-year period ending with the 2028 International Guideline update.
Why was PCOS renamed?
The old name implied the condition was defined by ovarian cysts. Research shows there are no abnormal cysts, only arrested follicles. The condition also affects hormones, metabolism, mental health, skin, and reproduction.
Can I still get pregnant with PMOS?
Yes. PMOS is a leading cause of female infertility, but many women conceive with treatment. Approaches include lifestyle and metabolic management, ovulation induction with oral medications, IUI, and IVF when appropriate.
Will my PCOS treatment change under the new name?
No. Treatment depends on your symptoms and goals, not on the name. Medications, monitoring, and follow-up plans continue as before. The new name reinforces a broader approach already used by fertility specialists.
When will the new name be officially adopted?
A three-year transition period began in May 2026. Both names will appear in clinical settings during this period. Full adoption is scheduled for the 2028 International Evidence-Based Guideline update.